Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International

LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Biotechnology industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International. Register for these free reports at:

http://protraderdaily.com/register/

At the close of the Canadian markets on Tuesday, November 07, 2017, the Toronto Exchange Composite index ended the trading session at 16,131.79, 0.25% higher from its previous closing price.

The Healthcare Index was also in the black, closing the day at 77.13, up 3.98%.

Pro-Trader Daily's complimentary research reports on the following stocks are now available: Oncolytics Biotech Inc. (TSX: ONC), Aurinia Pharmaceuticals Inc. (TSX: AUP), Immunovaccine Inc. (TSX: IMV), and IntelliPharmaCeutics International Inc. (TSX: IPCI). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

Oncolytics Biotech Inc.

Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock advanced 1.79%, to finish Tuesday's session at $0.57 with a total volume of 23,160 shares traded. Over the last three months and the previous one year, Oncolytics Biotech's shares have surged 14.00% and 128.00%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading below its 50-day and 200-day moving averages. Oncolytics Biotech's 50-day moving average of $0.61 is above its 200-day moving average of $0.60. See our research report on ONC.TO at:

http://protraderdaily.com/optin/?symbol=ONC

Aurinia Pharmaceuticals Inc.

On Tuesday, shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. recorded a trading volume of 41,856 shares. The stock ended the day 1.50% lower at $7.22. Aurinia Pharma's stock has rallied 109.27% in the past one year. Shares of the Company, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally, are trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $8.30 is above its 50-day moving average of $7.82. The complementary research report on AUP.TO at:

http://protraderdaily.com/optin/?symbol=AUP

Immunovaccine Inc.

On Tuesday, shares in Halifax, Canada-based Immunovaccine Inc. ended the session 8.22% higher at $1.58 with a total volume of 181,243 shares traded. Immunovaccine's shares have surged 44.95% in the last one month and 36.21% in the previous three months. Furthermore, the stock has rallied 107.89% in the past one year. Shares of the Company, which develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform, are trading above its 50-day moving average of $1.26. Register for free and access the latest research report on IMV.TO at:

http://protraderdaily.com/optin/?symbol=IMV

IntelliPharmaCeutics International Inc.

Toronto, Canada-based IntelliPharmaCeutics International Inc.'s stock closed the day 0.85% lower at $1.16. The stock recorded a trading volume of 900 shares. Shares of the Company, which researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $2.07 is greater than its 50-day moving average of $1.25. Get free access to your research report on IPCI.TO at:

http://protraderdaily.com/optin/?symbol=IPCI

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily